Xiao et al., 2020 - Google Patents
Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patientsXiao et al., 2020
View PDF- Document ID
- 13194474104677148281
- Author
- Xiao Q
- Zhou Y
- Winter S
- Büttner F
- Schaeffeler E
- Schwab M
- Lauschke V
- Publication year
- Publication venue
- International Journal of Cancer
External Links
Snippet
Multidrug resistance due to facilitated drug efflux mediated by ATP‐binding cassette (ABC) transporters is a main cause for failure of cancer therapy. Genetic polymorphisms in ABC genes affect the disposition of chemotherapeutics and constitute important biomarkers for …
- 206010006187 Breast cancer 0 title abstract description 67
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yee et al. | Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium | |
Xiao et al. | Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients | |
Low et al. | Breast cancer: The translation of big genomic data to cancer precision medicine | |
Bhatia | Genetics of anthracycline cardiomyopathy in cancer survivors: JACC: CardioOncology state-of-the-art review | |
Wheeler et al. | Cancer pharmacogenomics: strategies and challenges | |
Argyriou et al. | Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics | |
Sheng et al. | MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case–control studies | |
Baker et al. | Pharmacogenetic pathway analysis of docetaxel elimination | |
Yamakawa et al. | Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia | |
Weiss | New approaches to personalized medicine for asthma: Where are we? | |
Fowler et al. | A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure | |
Russell et al. | Pharmacogenomics in the era of next generation sequencing–from byte to bedside | |
Woo et al. | Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma | |
Chen et al. | ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients | |
Han et al. | Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians | |
Han et al. | A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer | |
Wang et al. | Functional variant in the SLC22A3-LPAL2-LPA gene cluster contributes to the severity of coronary artery disease | |
Li et al. | The roles of variants in human multidrug resistance (MDR1) gene and their haplotypes on antiepileptic drugs response: a meta-analysis of 57 studies | |
Chu et al. | Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in Asian patients receiving sunitinib for renal cell carcinoma | |
Franke et al. | Influence of solute carriers on the pharmacokinetics of CYP3A4 probes | |
Erculj et al. | The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma | |
Neřoldová et al. | Rare variants in known and novel candidate genes predisposing to statin-associated myopathy | |
Sohn et al. | Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients | |
Ono et al. | Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions | |
Wang et al. | Clustered Mendelian randomization analyses identify distinct and opposing pathways in the association between genetically influenced insulin-like growth factor-1 and type 2 diabetes mellitus |